Choline benefits in children with fetal alcohol disorder may last for years

A follow-up study suggests that nine months of choline supplementation in early childhood may improve non-verbal intelligence and working memory years later, though larger trials are needed.

Choline supplements may offer children exposed to alcohol before birth a lasting boost in cognition, according to new research that adds to a small but growing body of evidence around one of the few treatments tested for fetal alcohol spectrum disorder.

Fetal alcohol spectrum disorder is an umbrella term for a range of conditions linked to prenatal alcohol exposure and can affect physical development, learning and behaviour. Researchers have long explored choline, an essential nutrient involved in brain development, because animal studies and earlier human work suggested it may help offset some of the effects of alcohol exposure during pregnancy.

In the latest study, published in Alcohol: Clinical & Experimental Research, scientists at the University of Minnesota looked again at children who had taken part in three randomised controlled trials of choline in early childhood. Those studies enrolled 104 children aged two to five, all diagnosed with some form of fetal alcohol spectrum disorder, and compared nine months of choline treatment with placebo in the 84 who completed a trial. In the new follow-up, 58 of those children, now about nine years old on average, were reassessed.

The results suggest the benefits may persist well beyond the original treatment period. Children who had received choline performed better on tests of certain cognitive skills than those given placebo, with higher average scores in non-verbal intelligence and working memory. The report also found that higher doses were associated with greater gains. A measure of inhibition, a component of executive function, showed a trend in the same direction but did not reach statistical significance. Other areas, including broader memory measures and parent-rated behaviour, did not show clear differences.

Earlier trials had already hinted at short-term improvements, particularly in sequential memory and delayed recall. Separate studies published in PubMed-indexed journals also found the treatment was generally well tolerated and feasible in young children, with some evidence of benefit for hippocampal-dependent memory and possible links between response and genetic differences in choline metabolism. Taken together, the research suggests choline may alter a child’s developmental trajectory rather than simply produce a temporary effect.

Even so, the work remains preliminary. The researchers say larger studies are still needed to determine the best dose, timing and length of treatment. For families and clinicians facing fetal alcohol spectrum disorder, however, the findings are notable because choline is one of the few biological interventions to have been tested repeatedly in randomised trials, and it may offer a practical, scalable option where treatment choices remain limited.